Advanced Catheter Therapies (ACT) is a medical technology company specializing in the development and commercialization of innovative catheter-based solutions. The company's flagship product, the Pressana Occlusion Perfusion Catheter (OPC), is designed to create a localized treatment chamber for the targeted delivery of therapeutic agents, particularly for below-the-knee (BTK) applications. This technology has received three FDA 510k clearances and multiple patents, making it the only FDA-approved drug delivery technology for BTK use currently on the market. ACT primarily focuses on research and development (R&D) and licensing, having raised $8.87 million since its inception in 2011, with a significant portion of its revenue coming from licensing fees. The company operates in the medical device market, serving healthcare providers and patients at risk of lower limb amputations. By improving blood flow to the legs, ACT aims to reduce the high mortality rates associated with lower limb amputations.

Keywords: catheter technology, drug delivery, FDA clearance, lower limb amputation, BTK applications, therapeutic agents, medical device, R&D, licensing, healthcare.